14158 Results (Page 352 of 567)
All Market Research Reports
Italy Hemophilia Market Analysis
Italy Hemophilia Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The ability of a person's blood to clot is impaired by haemophilia A and haemophilia B, two rare congenital lifelong bleeding disorders that can cause excessive bleeding and spontaneous bleeding into joints, which can cause joint damage and chronic pain and have a significant impact on quality of life. The rise in haemophilia prevalence, improvements in treatment technology, and supportive governmental activities for haemophilia management are all contributing factors to the market share growth for haemophilia treatments. In the "Global Hemophilia market," the following firms are described: Baxalta, CSL Behring, Pfizer, Inc., Bayer Healthcare, BioMarin Pharmaceutical, Inc., Biogen, Chugai Pharmaceutical Co., Novo Nordisk, Shire Plc., Baxter International, Inc., and Hospira Inc.
Australia Glioblastoma Multiforme Therapeutics Market Analysis
Australia Glioblastoma Multiforme Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The most aggressive primary brain tumour is glioblastoma, also known as glioblastoma multiforme (GBM), which makes up for 15% of all intracranial neoplasms and 49% of malignant brain tumours. GBM is more common and has a worse prognosis as people age. It is still very difficult to increase the overall survival (OS) and progression-free survival (PFS) of GBM patients. Consequently, the GBM market has drivers. It is still very difficult to increase the overall survival (OS) and progression-free survival (PFS) of GBM patients. Global The following companies are significant players in the market: Arbor Pharmaceuticals, LLC, Amneal Pharmaceuticals, Karyopharm Therapeutics, Inc., Sumitomo Dainippon Pharma Oncology, Inc., Merck & Co., Inc., Amgen, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Amgen, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd. (Boston Biomedical, Inc.)
UAE Non Alcoholic Steatohepatitis (NASH) Therapeutics Market Analysis
UAE Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A number of factors, including the rising prevalence of non-alcoholic steatohepatitis, the rising incidence of chronic illnesses linked to it, the rising adoption of sedentary lifestyles, the rising awareness of health issues, etc., have contributed to the growth of the non-alcoholic steatohepatitis market over the past few years. Major global players in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market are Intercept Pharmaceuticals, Inc. Novartis AG,Siemens Healthineers AG, AstraZeneca PLC, Galectin Therapeutics Inc., GENFIT S.A., Madrigal Pharmaceuticals, Inc., Inventiva S.A., ONE WAY LIVER, S.L., Galmed Pharmaceuticals Ltd., Cirius Therapeutics, Prometheus Laboratories Inc., BioPredictive.
Canada Hypertrophic Cardiomyopathy Therapeutics Market Analysis
Canada hypertrophic cardiomyopathy therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. In addition to heart diseases, the market for therapies for hypertrophic cardiomyopathy is primarily driven by rises in the frequency of obesity and sedentary behaviour. Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., and Bayer AG are a few of the businesses now dominating the global hypertrophic cardiomyopathy therapeutics market.
Germany Scleroderma Therapeutics Market Analysis
Germany Scleroderma Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The rapid rise in scleroderma prevalence, rising frequencies of genetic anomalies, and considerable environmental changes occurring all over the world are all predicted to accelerate market expansion.Major global players in Scleroderma Therapeutics Market are Emerald Health Pharmaceuticals, Argentis Pharmaceuticals, LLC., F. Hoffmann-La Roche Ltd, AbbVie Inc., Pfizer Inc., Corbus Pharmaceuticals Holdings, Inc., Boehringer Ingelheim International GmbH, Sanofi, Allergan, viDA Therapeutics Inc., Novartis AG, Active Biotech AB., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Kadmon Holdings, Inc., Johnson & Johnson Private Limited, Liminal BioSciences Inc and AstraZeneca.
Italy Hemostasis Products Market Analysis
Italy Hemostasis Products market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for hemostasis products is growing rapidly as a result of rising prevalence of cardiovascular diseases worldwide due to adoption of unhealthy lifestyle, consumption of unhealthy food products and rising illnesses among the population, rising medical tourism, higher investments by government in research and development of hemostasis products, huge base of geriatric population coupled with large number of blood disorders patient population, increasing demand for minimally invasive surgeries, adoption of advanced hemostasis products by patients . Abbott Laboratories, Baxter International, CSL Behring, Hem Con Medical Technologies, Grifols, Johnson & Johnson, Medtronic, Pfizer, integra Life Sciences Corporation, C. R. Bard, Inc. are the key market players operating in global hemostasis products market.
India Alport Syndrome Therapeutics Market Analysis
India during the forecast period of 2023-30, the Alport Syndrome therapeutics market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. Almost always affecting the kidney, Alport syndrome is a multisystem condition that also usually affects the inner ear and the eye. A variety of symptoms that normally start in childhood or adolescence and may get worse over time can be present. Invitae Corporation, Hoffmann-La Roche Ltd., Centogene N.V., and Eurofins Discovery are a few of the leading companies in the worldwide Alport syndrome market.
Australia Glioma Therapeutics Market Analysis
Australia Glioma Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Brain and spinal cord tumours called gliomas attack the glial cells in the brain. Positive regulatory environments and the rising prevalence of gliomas are two variables that are expected to drive market expansion. Having a robust pipeline is anticipated to be a key factor in driving the market for glioma therapeutics during the course of the projected period. Over the course of the projected period, it is anticipated that the prevalence of brain tumours would spur market expansion. Global companies in the Glioma Therapeutics Market are Thermo Fisher Scientific Inc., Emcure Pharmaceuticals Ltd., Sigma-Aldrich Co., Pfizer Inc, Taj Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., GE Healthcare, Siemens Healthineers, Sun Pharmaceutical Industries, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation, Merck & Co., Inc., F. Hoffmann-Le Roche AG, Arbor Pharmaceuticals LLC Ltd., Novartis International AG, Amneal Pharmaceuticals. LLC, AstraZeneca, Carestream Health, Hitachi Medical Corporation.
UAE Optic Neuritis Therapeutics Market Analysis
UAE Optic Neuritis Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The rising incidence of optic neuritis is anticipated to fuel market expansion on a global scale. The rising prevalence of multiple sclerosis may be a major market driver. The usage of intravenous steroids such as prednisone, prednisolone, and others are anticipated to increase, which will help support market expansion. Major global players in Optic Neuritis Therapeutics Market are AbbVie Inc., Bausch & Lomb Incorporated, Boehringer Ingelheim International GmbH, Novartis AG, Merck & Co., Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi USA, Teva Pharmaceuticals Industries Ltd., GSK plc, Pfizer, Akorn Operating Company LLC, AdvaCare Pharma, Bristol- Myers Squibb Company, Jubilant Cadista Pharmaceuticals Inc., Amneal Pharmaceuticals LLC., Viatris Inc., and Novitium Pharma.
Canada Hypophosphatasia (HPP) Therapeutics Market Analysis
Canada hypophosphatasia (HPP) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for hypophosphatasia is anticipated to grow as a result of an increase in the ailment's prevalence, a family history of it, a robust product pipeline, and increased financing for research to create cutting-edge, new treatments for the condition. Major global players in the hypophosphatasia therapeutic market are Kirin Holdings Company Limited, Vericel Corporation, Mereo Biopharma Group Plc., Novartis AG, AM-Pharma B.V., Bayer AG, Pfizer Inc, Ultragenyx Pharmaceutical Inc, BioMarin Pharmaceutical Inc, Prior Company Ltd, Enobia Pharma Corporation, AstraZeneca Plc, Rallybio Corporation.
Germany Spinal Muscular Atrophy (SMA) Therapeutics Market Analysis
Germany Spinal Muscular Atrophy (SMA) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market is expanding as a result of rising SMA instances, technological advancements, government encouragement, rising consumer awareness, and increased R&D activities. Major global players in Spinal Muscular Atrophy (SMA) Therapeutics Market are Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Boehringer Ingelheim International GmbH. (Germany), GSK plc (U.K.), Novartis AG (Switzerland), Biogen (U.S.), Pfizer Inc.(U.S.), Ionis Pharmaceuticals, Inc. (U.S.), Regeneron Pharmaceuticals Inc (U.S.)., Abbott (U.S.), AbbVie Inc. (U.S.), Novo Nordisk A/S (Denmark), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca (U.K.), Leadiant Biosciences, Inc.(Italy), Catalyst Pharmaceuticals, Inc.(U.S.), PTC Therapeutics (U.S.)
Italy Hereditary Angioedema Drugs Market Analysis
Italy Hereditary Angioedema Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Hereditary Angioedema Drugs is growing as a result of Increasing Awareness and Diagnosis of disease, Advancements in Treatment Options, Technological Advancements and the regulatory authorities have designated numerous HAE therapies as orphan drugs as a result of this classification, pharmaceutical companies are given some incentives including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas. Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these organisations.
India Anal Fistula Therapeutics Market Analysis
India During the forecast period of 2023?2030, the Anal Fistula Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. A rare intestinal ailment that typically appears following an acute perianal abscess and is defined by improper connection between the lower rectum and the perianal skin. The market is expanding more quickly thanks to technological advancements in anal fistula therapy. The development of novel surgical treatment options and the explosive growth of the medical tourism business have contributed to the sector's segment expansion. The leading companies profiled in the market research study on anal fistula treatment include Becton, Medtronic, Dickinson and Company, Gem Srl, Biolitec AG, BD, Johnson & Johnson Services, Inc., Mylan N.V., Takeda Pharmaceutical Company Limited, W. L. Gore & Associates, Cook, KARL STORZ SE & Co. KG, Novartis AG, Boehringer Ingelheim International GmbH, Pfizer.
Australia Guillain-Barre Syndrome (GBS) Therapeutics Market Analysis
Australia Guillain-Barre Syndrome (GBS) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Guillain Barre Syndrome is a rare autoimmune disorder in which persons immune system attacks nervous system. The market for Guillain-Barre Syndrome (GBS) drugs is growing rapidly as a result of increase in the incidence and prevalence of the guillain-barre syndrome, advancements in technology and development in healthcare, support and funding by governments globally, rise in the geriatric population and increase in the prevalence of chikungunya and immune diseases like multiple sclerosis , increase in the approvals of immunoglobulins by regulatory bodies and increase in research and development activities by pharmaceutical companies. Alexion Pharmaceuticals Inc., Annexon Inc., Cellenkos Inc., Cresence AS, Akari Therapeutics Plc, Chugai Pharmaceutical Co Ltd are the key market players operating in global gullian barre syndrome drugs market.
UAE Ovarian Cancer Therapeutics Market Analysis
UAE Ovarian Cancer Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors driving the growth of the ovarian cancer market is the rising prevalence of the disease. Other important drivers are the development of new therapies and treatments, rising healthcare expenses, and increased government support. Due to greater public awareness of healthcare issues, the market for ovarian cancer is also expanding. Major global players in Ovarian Cancer Therapeutics Market are Allergan Plc, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, Syndax, Clovis Oncology, Boehringer Ingelheim International GmbH., GlaxoSmithKline plc., Exelixis, Inc., KINTARA THERAPEUTIC, INC., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Private Limited, AbbVie Inc.
Canada Interstitial Cystitis Therapeutics Market Analysis
Canada Interstitial Cystitis Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 30. The global market is expanding as a result of a rise in the frequency of interstitial cystitis and support for research. Major global players in this market are Amneal Pharmaceuticals Inc, Astellas Pharma Inc, Aurobindo Pharma Ltd, Bayer AG, Cadila Healthcare Ltd, Eli Lilly and Co, Hikma Pharmaceuticals Plc, Intas Pharmaceuticals Ltd, Johnson and Johnson, Kyorin Pharmaceutical Co. Ltd, Mission Pharmacal Co, Perrigo Co. Plc, Pfizer Inc, Purdue Pharma LP, Seikagaku Corp, Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Viatris Inc.
Germany Von Willebrand Disease Therapeutics Market Analysis
Germany Von Willebrand Disease Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Some of the key factors influencing market growth include the introduction of new von Willebrand disease therapies, rising awareness of the condition due to an increase in government initiatives and awareness campaigns, and expanding partnerships and collaborations between top research institutions and regulatory bodies. Major global players in Von Willebrand Disease Therapeutics Market are Octapharma AG Grifols, S.A. Shire plc Bayer AG CSL Behring Pfizer, Inc. Akorn, Inc. Ferring B.V.
Italy Hodgkins Lymphoma Drugs Market Analysis
Italy Hodgkins Lymphoma Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030.The market for Hodgkins Lymphoma Drugs is rising due to Increasing incidence of Hodgkin lymphoma, Extensive research and development activities, Growing adoption of immunotherapies, Increasing awareness and diagnosis about disease, Improved reimbursement policies and increased insurance coverage for cancer treatments along with growing availability of targeted therapies and combination therapies for Hodgkin Lymphoma Drugs. Bristol Myers Squibb, Merck & Co., Inc. (MSD), Takeda Pharmaceutical Company Limited, Roche Holding AG, Novartis AG, Pfizer Inc., AstraZeneca plc, Johnson & Johnson, AbbVie Inc., Celgene Corporation (a subsidiary of Bristol Myers Squibb), Amgen Inc., Gilead Sciences, Inc. are the global companies in Hodgkins Lymphoma Drugs market.
India Angelman Syndrome Therapeutics Market Analysis
India During the forecast period of 2023?2030, The Angelman Syndrome Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. An uncommon inherited neuro-developmental condition called Angelman Syndrome is marked by a severe developmental delay, sleep issues, jerky movements, and a lot of laughter. As the illness is more common, there are more government measures to manage it. This has also helped with research and development for condition treatment. These factors collectively represent the Angelman Syndrome Therapeutics Market's driving forces. Boston Children's Hospital, the Angelman Syndrome Foundation, Rady Children's Hospital in San Diego, General Hospital Corporation, Cincinnati Children's Hospital Medical Center, and others are major competitors in the market for treating Angelman syndrome.
Australia Hemophilia A Therapeutics Market Analysis
Australia Hemophilia A Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A lack of or failure with regard to clotting factor VIII characterises the rare inherited bleeding condition known as haemophilia A. It is the most prevalent form of haemophilia and primarily affects men, though it can also afflict women who carry the gene mutation. Hemophilia A market development goes beyond traditional markets, with a stronger emphasis on increasing access to care in developing markets. In areas where access to specialised care and therapies may be restricted, efforts are being made to improve diagnosis, treatment infrastructure, and pricing. Some of the notable companies operating in the Hemophilia A therapeutics market include BioMarin Pharmaceutical Inc, Bayer AG, Pfizer Inc., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., Shire (now part of Takeda Pharmaceutical Company Limited), CSL Behring LLC, Sanofi S.A., Grifols S.A. and Octapharma AG.
UAE Paroxysmal Noctural Hemglobinuria (PNH) Therapeutics Market Analysis
UAE Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Paroxysmal Nocturnal Hemoglobinuria Therapeutics is being driven by reasons like the rise in blood and bone marrow abnormalities, population ageing, rising disposable income, unmet demand for PNH treatment, and technological improvements in stem cell transplantation. Major global players in Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market are Achillion Pharmaceuticals Akari Therapeutics Alexion Pharmaceuticals Amgen Inc. Apellis Pharmaceuticals F. Hoffmann-La Roche AG. GE Healthcare Johnson & Johnson Ra Pharmaceuticals Regeneron Pharmaceuticals, Inc. Takeda Pharmaceutical Company Limited (Shire Plc) Thermo Fisher Scientific Inc.
Germany Wilson?s Disease Therapeutics Market Analysis
Germany Wilson?s Disease Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Wilson?s Disease Therapeutics is growing rapidly as a result of rising prevalence of the disease, advancements in diagnostic techniques, increase in awareness about the disease due to patient advocacy programmers, support and incentives from regulatory authorities like incentives and orphan drug designations and increasing investment in research and development activities. Amneal Pharmaceuticals, Meda Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Taj Pharmaceutical Limited, Ipsen Pharma, TSUMURA & CO., Mylan pharmaceuticals are the key global market players in Wilson?s Disease Therapeutics market.
Italy Huntington's Disease Drugs Market Analysis
Italy Huntington's Disease Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for treating Huntington's disease is expanding due to a number of causes, including an increase in the disease's prevalence and a rise in the demand for modern drug types to treat the signs and symptoms of the disease especially rise in disease modifying therapies, incentives provided by regulatory authorities like orphan drug designations. Some of the key players in the global Huntington's Disease Drugs Market include Pfizer, Inc. Alnylam Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd. Neurocrine Biosciences, Inc. Ionis Pharmaceuticals, Vertex Pharmaceuticals Incorporated (U.S.), Elekta AB (Sweden), Alterity Drugs(Australia) and som biotech (spain).
India Ankylosing Spondylitis Therapeutics Market Analysis
India Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.
Australia Hemophilia B Therapeutics Market Analysis
Australia Hemophilia B Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The rare genetic bleeding illness known as haemophilia B is brought on by a lack of or malfunction in the clotting factor IX. The increasing prevalence of haemophilia B, improvements in available treatments, and greater public knowledge of the condition have all contributed to the steady growth of the global market for therapies for the condition. However, because Hemophilia B is less common than Hemophilia A, the market for therapies for this condition is smaller than it is for Hemophilia A. Takeda Pharmaceutical Company Limited (previously Shire), Takeda Pharmaceutical Company Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, CSL Behring LLC, Sanofi S.A., Grifols S.A., Octapharma AG, and others are notable market participants.
